However, the drug belonging to the classes of SGLT2 inhibitors did not demonstrate statistically significant benefits for the prevention of heart or stroke attacks even in patients with diagnosed cardiovascular disease.
Diabetics have a greater risk of heart problems, which makes cardiovascular diseases beneficial for doctors and patients.
Stephen Wiviott Brigham and the Boston Women's Hospital, the leading researcher of this cynical investigation, said that these findings are important for a clear picture of the SGLT2 drugs that have so far been addressed to patients with diagnosed carcasses.
AstraZeneca hopes new information will help extend Farxigan's use to a broader patient group.
The key findings of 17,000 cohort clinical trials were released in September but details were unveiled on Saturday at the American Heart Association annual meeting and published at the same time in the New England Journal of Medicine.
These results have shown that Farxiga reduces the risk of cardiovascular disease and kidney disease risk by 27%.
Although two smaller studies involving competing SGLT2 drugs have focused on patients diagnosed with heart disease, Wiviott said the overall picture of the published study showed that major prevention of heart attacks is a primary benefit.
"When we analyze three studies, it is clear that the primary benefit of this class of cardiovascular disease is to reduce heart failure," Wiviott said.
For decades, diabetologists have focused primarily on lowering the blood glucose level at certain levels. Diabetes's tendency to other things, such as heart failure, with a five-year survival rate of only 50 percent, indicates that a more holistic approach is needed, "Wiviott says.
"The message right now is how we can reduce glucose levels, it may be as important as our share. We should choose medicines that improve patient life expectancy, not just medicines that have efficacy in reducing blood glucose," the doctor said.
Farxiga competes with competing SGLT2 medicines, including Jardiance, produced by Eli Lilly and Boehringer Ingelheim and Invokana Johnson & Johnson, who have already shown a prolongation of life expectancy for patients with diagnosed cardiac problems, so-called secondary contraception.
Since the AstraZeneca study also evaluated patients who did not diagnose cardiovascular disease, the study will open up a wider market, including primary prevention.
Declare did not detect an increased risk of amputations, fractures, bladder or gangrene in patients treated with Farxiga occasionally observed in SGLT-treated patients but genital infections have increased.